Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna - 210 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- 3Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- 4When a sperm whale gives birth, the mother gets help from her friends
- 5Multi-million-euro win in Spanish lottery in doubt due to oversight
- Single women risk rape and exploitation in search for better life in Europe
- Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- Historical mysteries solved by science in 2025
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- The wolf supermoon will kick off 2026 with a celestial bang. Here's when and how to see it.
- 'Wow!' The eye surgery marathon that restored sight for some South Africans
- Select Your Definitive Pizza Decision
- 5 Must-Attempt Fascinating Dishes from Around the World
- Choosing Moving Styles for Your Restroom Redesign
